HIPEC in ovarian cancer: What should we expect?

被引：1
|
作者：
Picard, Leonie [1 ]
Bourgin, Charlotte [2 ]
Penault-Llorca, Frederique [1 ]
Beguinot, Marie [1 ]
Cornou, Caroline [1 ]
Le Bouedec, Guillaume [1 ]
Mouret-Reynier, Marie-Ange [1 ]
Selle, Frederic [3 ]
Pomel, Christophe [1 ]
机构：
[1] Ctr Jean Perrin, 58 Rue Montalembert, F-63011 Clermont Ferrand, France
[2] Inst Cancerol Ouest, 15 Rue Andre Boguel, F-49055 Angers, France
[3] Hop Diaconesses, 12-18 Rue Sergent Bauchat, F-75012 Paris, France
来源：
BULLETIN DU CANCER | 2019年 / 106卷 / 11期
关键词：
HIPEC; Ovarian; Carcinomatosis; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INTERVAL DEBULKING SURGERY; CYTOREDUCTIVE SURGERY; ONCOLOGY-GROUP; STAGE-III; DOUBLE-BLIND; CISPLATIN; BEVACIZUMAB; PACLITAXEL; MULTICENTER;
D O I：
10.1016/j.bulcan.2019.04.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The results of PRODIGE 7 study demonstrate that the use of HIPEC is not beneficial for patients in the treatment of colorectal carcinomatosis. Nevertheless, a recent study published in New England Journal of Medicine showed that hyperthermic intraperitoneal chemotherapy (HIPEC) increased overall survival for patients with ovarian peritoneal carcinomatosis. Although, the emergence of targeted therapies (anti-angiogenic agents, PARP-inhibitors, anti-PDL1) results in new standards of treatment in first line or recurrence disease. In this general context, what is the potential interest of HIPEC for the treatment of ovarian carcinoma?
引用
收藏
页码：1023 / 1028
页数：6
相关论文
共 50 条
  • [31] Second-line chemotherapy in head and neck cancer: what should we expect?
    Buentzel, Jens
    Micke, Oliver
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (03) : 269 - 273
  • [32] Changes in Gleason Scores for Prostate Cancer: What Should We Expect From a Measurement?
    Ramos, Jorge
    Uchio, Edward
    Aslan, Mihaela
    Concato, John
    JOURNAL OF INVESTIGATIVE MEDICINE, 2010, 58 (04) : 625 - 628
  • [33] Ongoing trials: What should we expect after ALLHAT?
    Ji-Guang Wang
    Jan A. Staessen
    Anthony M. Heagerty
    Current Hypertension Reports, 2003, 5 : 340 - 345
  • [34] EXTRACELLULAR MATRIX OF SENESCENT CELLS: WHAT SHOULD WE EXPECT?
    Ferreira, Rita Sa
    Pitrez, Patricia
    Quaas, Maximilian
    Pompe, Tilo
    Ori, Alessandro
    Passos, Joao
    Ferreira, Lino
    TISSUE ENGINEERING PART A, 2022, 28 : S561 - S561
  • [35] The rise of HIPEC in ovarian cancer treatment: Are we still there?
    Kapoor, Rohan
    Ray, M. D.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2025, 21 (01) : 180 - 181
  • [36] The Effects of the Sunshine Act: What Can and Should We Expect?
    Sinha, Michael S.
    Kesselheim, Aaron S.
    AMERICAN JOURNAL OF BIOETHICS, 2017, 17 (06): : 22 - 24
  • [37] CLINICAL-TRIALS OF RADIOSENSITIZERS - WHAT SHOULD WE EXPECT
    BROWN, JM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (03): : 425 - 429
  • [38] What should we expect from the regulation of glycemic variability?
    Gomez, Manuel Delgado
    AVANCES EN DIABETOLOGIA, 2014, 30 (03): : 63 - 71
  • [39] Planning for the next influenza pandemic: What should we expect?
    Lockman, Justin L.
    Nichols, David G.
    PEDIATRIC CRITICAL CARE MEDICINE, 2011, 12 (03) : 371 - 372
  • [40] Ongoing trials: What should we expect after ALLHAT?
    Wang, JG
    Staessen, JA
    Heagerty, AM
    CURRENT HYPERTENSION REPORTS, 2003, 5 (04) : 340 - 345
12345